AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03742622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EX+R. condition with an acute exercise set in the morning and followed by a energy replacement snack
Description: EX+R. condition with an acute exercise set in the morning and followed by a energy replacement snack The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) in the morning followed by a snack that will cover the whole exercise-induced energy expenditure. They will then receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
Study NCT02563119 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Bypass or Sleeve gastrectomy
Study NCT04042298 — intervention group
Intervention type: OTHER
Intervention: Arterial blood pressure
Description: Measured using an automated non-invasive finger cuff that obtains beat-by-beat blood pressure measurements via finger photoplesmography. Briefly, changes in artery diameter are detected through infrared light in the finger cuff. (Finometer Pro, FMS, The Netherlands).
Study NCT04042298 — intervention group
Intervention type: OTHER
Intervention: Skin microcirculatory blood flow
Description: Assessed non-invasively in the forearm skin via Laser Doppler flowmetry in response to locally delivered acetylcholine and norepinepherine or phenylepherine via iontophoresis.
Study NCT04042298 — intervention group
Intervention type: OTHER
Intervention: Brachial artery blood flow
Description: A GE Ultrasound System will be used to non-invasively assess brachial artery blood flow prior to and following a standard flow mediated dilation protocol.
Study NCT04042298 — intervention group
Intervention type: OTHER
Intervention: Venous blood draw
Description: A venous blood sample from the antecubital vein or a vein in the back of the hand will be taken via venipuncure by a nurse or a certified phlebotomist at the beginning of the experimental visit. These blood samples will be analyzed for the presence of reactive oxygen species and inflammatory markers.
Study NCT01589341 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03584074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 75mg
Description: Orally taken twice daily for 8 weeks
Study NCT03584074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celebrex 200Mg Capsule
Description: Orally taken once daily for 8 weeks
Study NCT03584074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celebrex 200Mg Capsule
Description: Orally taken once daily for 8 weeks
Study NCT04015583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exergaming group
Description: Exergame is 'exercise + game'. Treadmill exercise is traiditional aerobic exercise
Study NCT01179802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strenuous Endurance exercise
Description: Jungfraumarathon: Mountain-Marathon with a length of 42km and a altitude-difference of approximately 1830meters.
Study NCT01709006 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions
Description: Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions
Study NCT01303887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Vincristine 1.4mg/m2 IV day 1,repeated every 21 days for 8 cycles.
Study NCT01303887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone 40mg/m2 PO day 1-5, repeated every 21 days for 8 cycles.
Study NCT02548299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: Nutrition classes will be led by a registered dietician.
Study NCT02548299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cooking Lecture
Study NCT02548299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cooking Demo
Study NCT02548299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hands-on Cooking
Study NCT03152734 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical or non-surgical intervention
Description: Each kind of surgical or non-surgical intervention with anesthesia applied by an anesthetist
Study NCT02548299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Coaching
Study NCT01124942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MGuard net protective coronary stent
Description: It is a new closed-cell design stent concept. with an ultra-thin flexible polyethylene terephthalate (or Dacron) mesh sleeve, anchored to the external surface of the struts. This net (string diameter 10-22 μm) minimally affects stents' trackability and deliverability. During stent deployment, the net stretches and slides over the expanding stent struts, trapping the thromboembolic debris underneath the fiber net.
Study NCT01124942 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare-metal stent and manual thrombectomy device
Description: Manual thrombectomy device as an adjunctive strategy for conventional stenting with a bare-metal stent
Study NCT03347396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIVV009
Description: Sutimlimab was administered as intravenous (IV) infusion.
Study NCT01847534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplemental PN
Study NCT03043300 — intervention group
Intervention type: OTHER
Intervention: Long-Term Post-Travel Questionnaire
Description: The long-term post-travel questionnaire is a 16 item instrument collecting information about illnesses since last study visit, dietary habits since last study visit, and any traveling since the last visit.~This questionnaire will be administered verbally by the study team and completed 14 weeks after returning to the United States from travel.
Study NCT03043300 — intervention group
Intervention type: OTHER
Intervention: Long-Term Post-Travel Stool Specimen Collection
Description: The short-term post-travel stool specimen collection will occur 14 weeks after returning to the United States from travel.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention.
Study NCT00675844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elvucitabine
Description: 10 milligrams (mg) elvucitabine daily as part of an ART regimen
Study NCT01303887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 40mg/m2 PO day 1-3,repeated every 21 days for 4 cycles
Study NCT02913547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silk'n HST
Description: Treatment with Silk'n HST on the periorbital area as instructed in the user's manual
Study NCT04098029 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low HLA group CBU infusion
Description: CB-MNC (Cord Blood Mononuclear Cells) infusion from different donors. One dose consists of 2-15х10\^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of CB is 3 or fewer by A, B, DRB1 loci.
Study NCT04098029 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High HLA group CBU infusion
Description: CB-MNC (Cord Blood Mononuclear Cells) infusion from different donors. One dose consists of 2-15х10\^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of CB is 4 or more by A, B, DRB1 loci.
Study NCT04098029 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard therapy
Description: The standard therapy can include drugs, special psychology training, etc.
Study NCT06220227 — intervention group
Intervention type: PROCEDURE
Intervention: vitrification and thawing procedures
Description: Vitrification and thawing are crucial steps in infertility treatment. Vitrification solutions are aqueous cryoprotectant solutions that undergo solidification (and not freezing) when cooled at high rates to very low temperatures, thanks to an increase in viscosity.~Thawing consists in remove the cryoprotectants, warm and dilute the blastocyst.
Study NCT05874947 — intervention group
Intervention type: DEVICE
Intervention: linear measurement
Description: Linear measurements from digital caliper ,CBCT and EOS generated digital dental models
Study NCT03172013 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet indices
Description: MPV, PDW
Study NCT02051829 — intervention group
Intervention type: OTHER
Intervention: Comparison of the four screening score
Description: Comparison of the four screening score, for patient making a preoperative assessment for SLBO (clinique Saint-Luc de BOuge)
Study NCT01465087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NA-NOSE artificial olfactory system
Description: NA-NOSE is an artificial olfactory system that is based on nanomaterials and connected with machine learning. NA-NOSE can diagnosis diseases or disorders based on volatile biomarkers that are emitted from exhaled breath, blood, or from clinical tissue.
Study NCT01189214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Add-on of memantine or placebo treatment will proceed in a double-blinded fashion for 12 weeks after adjusted methadone dose. During the study, we will evaluate treatment response and adverse effect from multiple dimensions to elucidate the therapeutic effect of add-on memantine on addictive behaviors. It will also explore the possible advantage of this treatment on social re-adaptation and psychopathogenesis of opioid dependence.
Study NCT05110820 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Automated quantitative pupillometer
Description: Quantitative measurement of pupillary variables was performed at the time of arrival at the ED (0 h), and at the 6-, 12-, and 24-h time points on hospital day (HD) 1. The worst value among those recorded within 24 h and during the total measurement period was selected as the 24-h and total lowest values. If a patient was discharged before HD 3, measurements were taken only until discharge. The initial value was measured within 1 h after arrival at the ED because of the requisite time for obtaining informed consent before enrollment. At each time point, the lowest values for the NPi and qPLR of each eye were retained for analysis. The sPLR (standard PLR) was serially measured in the ED and after admission by emergency physicians using a manual penlight. We classified the reactivity of the sPLR as reactive, sluggish, or non-reactive. Non-reactive sPLR was defined when pupillary reactivity was not identified bilaterally.
Study NCT01847534 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Study NCT01444326 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dairy
Description: During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy (375 ml of milk, 175 g of yogurt, 30 g of cheese) into their every day diet.~During the CONTROL arm of the study, participants will be asked to consume energy equivalent replacement products (375 ml of fruit juice, 1 homemade cookie, 20 g of cashew).
Study NCT01444326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dairy
Description: During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy (375 ml of milk, 175 g of yogurt, 30 g of cheese) into their every day diet.~During the CONTROL arm of the study, participants will be asked to consume energy equivalent replacement products (375 ml of fruit juice, 1 homemade cookie, 20 g of cashew).
Study NCT04516590 — intervention group
Intervention type: OTHER
Description: There was no intervention in this observational study
Study NCT02337114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: A psychotherapeutic intervention that aims to enhance individuals' willingness to have difficult experiences but persist with behaviours that reflect what is important to them.
Study NCT00425373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan + amlodipine 40/2.5 mg
Description: Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
Study NCT00425373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan + amlodipine 40/5 mg
Description: Valsartan + amlodipine 40/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
Study NCT00425373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan + amlodipine 80/2.5 mg
Description: Valsartan + amlodipine 80/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
Study NCT00425373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan + amlodipine 80/5 mg
Description: Valsartan + amlodipine 80/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
Study NCT00425373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 40 mg
Description: Valsartan 40 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
Study NCT00425373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 80 mg
Description: Valsartan 80 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
Study NCT02848157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients are put in lithotomy position. Two separate injection points are marked at 3 and 9 o'clock, about 2 to 2.5 cm from the center of anus. After aseptic preparation, a nerve stimulator needle advanced 1.5 to 3.5 cm perpendicular to the skin, and stimulation current is 2.5 to 5 mA. The unilateral contraction of anal sphincter means the inferior anal nerve stimulation. After reducing the current to 0.5 mA, the needle is then moved deeper until an up-and-down penile movement is observed. This is stimulation of the perineal branch of the pudendal nerve. Prepared drug (0.25% ropivacaine and 0.3 mcg/kg dexmedetomidine in the experimental group, and equivalent doses of ropivacaine and normal saline in the control group) is injected in half and half bilaterally.
Study NCT02848157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: plain ropivacaine
Description: ropivacaine and normal saline equivalent doses of dexmedetomidine
Study NCT02848157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Study NCT03752359 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein
Description: This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 16 weeks. At the beginning and end of the experiment, two weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
Study NCT03752359 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 16 weeks. At the beginning and end of the experiment, two weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
Study NCT01053611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol + remifentanil 0 ng/ml
Description: remifentanil 0 ng/ml
Study NCT01053611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol + remifentanil 2 ng/ml
Study NCT01053611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol + remifentanil 4 ng/ml
Study NCT01053611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol + remifentanil 6 ng/ml
Study NCT01053611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol + remifentanil 0 ng/ml
Study NCT03330548 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TeleMOVE!
Description: Active comparator- telehealth treatment program for weight management and health promotion
Study NCT03330548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culinary Rx
Description: Experimental Arm- An online instructional cooking and nutrition course to promote a whole-foods, plant-based lifestyle.
Study NCT01383551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Becoming Parents intervention
Description: A Becoming Parents programme consists of: (i) 3 antenatal workshops conducted over a period of 10-14 weeks in prenatal period; and (ii) support provided by trained volunteers for up to 3 months post-delivery; in addition to the usual prenatal education.
Study NCT03883295 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: The specimens will be root canal treated conventionally
Study NCT03883295 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NeoMTA Plus
Description: The specimens will be subjected to vital pulp amputation using NeoMTA Plus.
Study NCT04319835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OnZurf Probe
Study NCT02255162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Patients will receive lenalidomide starting on day 6 of each post-remission cycle, following conclusion of cytarabine post-remission therapy on days 1-5. Following count recovery in the third post-remission cycle, patients will then receive lenalidomide daily as a maintenance therapy.
Study NCT02255162 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HLA-mismatched stem-cell Microtransplantation
Description: Patient will receive HLA-mismatched stem cell microtransplant infusion on day 6 of each post-remission cycle, following conclusion of course of cytarabine in each cycle.
Study NCT02255162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Patients will receive cytarabine post-remission therapy for 3 cycles, on days 1-5 of each cycle.
Study NCT02646891 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent P2-VP8 Subunit Rotavirus Vaccine
Description: Manufactured and supplied by the Walter Reed Army Institute of Research (WRAIR) Pilot Bioproduction Facility (BPF). The trivalent P2-VP8 vaccine was formulated as a sterile suspension containing a total of 360 µg of protein (120 µg of each P type) per mL adsorbed to aluminum hydroxide (1.125 mg of aluminum per mL in a phosphate buffer, pH 7).
Study NCT02646891 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride 0.9%, USP for Injection
Study NCT02182856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 500 µg/salbutamol sulphate 3 mg
Study NCT02182856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium 500 µg
Study NCT02182856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol sulphate 3 mg
Study NCT02182856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol sulphate 6 mg
Study NCT01276795 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Nutrition Support
Description: The patients will sip the oral nutrition support (in the form of a drink) over the course of 4 hours within each 6 hour study. Each patient will be studied once before surgery and once after surgery.
Study NCT01276795 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral Nutrition Support
Description: The patients will sip the oral nutrition support (in the form of a drink) over the course of 4 hours within each 6 hour study. Each patient will be studied once before surgery and once after surgery.
Study NCT02835391 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PerClot
Description: Haemostatic device for the control of bleeding from capillary, venous or arteriolar vessels by pressure, ligature or other conventional means is either ineffective or impractical.
Study NCT02835391 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Floseal, Surgicel, Surgiflo, Arista
Description: Haemostatic device for the control of bleeding
Study NCT02835391 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocautery/Diatermy
Description: Procedure for the control of bleeding
Study NCT00807989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine
Study NCT00807989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine/Valproate
Study NCT00425373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 2.5 mg
Description: Amlodipine 2.5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
Study NCT00425373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 5 mg
Description: Amlodipine 5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
Study NCT00425373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 tablet and 2 capsule placebos taken once daily